November 18, 2025

Gut Microbes Signal CAD Risk

Metagenome analysis reveals strain-level functional differences and metabolic pathways that distinguish patients with coronary artery disease from healthy controls.

Conexiant

November 11, 2025

ED drugs tied to lower gastric cancer risk

Large retrospective study finds 30% reduction in gastric malignancy among men taking erectile dysfunction medications.

Conexiant

November 10, 2025

Gastric microbiome shifts track H pylori virulence

Pathogenic bacterial genotypes correlate with distinct microbial communities; overall α-diversity is unchanged, but virulent strains show greater diversity within subgroups as atrophy progresses

Conexiant

November 06, 2025

CRC screening: Smartphone-based stool test matches lab accuracy

The findings point to a new tool for enhancing participation in CRC screening programs—particularly among younger, tech-savvy patients under 60 years who demonstrated higher adoption rates.

Conexiant

November 06, 2025

Exercise Patterns and GI Cancer Risk

Consistently meeting—but not exceeding—recommended activity levels offers maximal protection against digestive cancers, new research suggests.

Conexiant

November 05, 2025

Bariatric surgery vs GLP-1s: GERD risk

Propensity-matched analysis of over 80,000 patients reveals bariatric surgery nearly doubles five-year esophageal complication rates compared with GLP-1 RA therapy.

Conexiant

November 05, 2025

Shame in Medicine—A Quiet Epidemic

A new movement in medicine aims to teach “shame competence,” helping physicians recognize and manage one of the field’s most corrosive yet overlooked emotions.

KFF Health News

November 04, 2025

New Poll: Only 1 in 3 Link Alcohol to Cancer

“Individuals who drink alcohol were more likely to believe that alcohol consumption has no effect on cancer risk, which is alarming, given the growing burden of alcohol-related cancers in the United States."

Conexiant

November 04, 2025

GLP-1s and Tirzepatide: Similar GI Risk

Real-world data show similar rates of severe GI events with semaglutide, dulaglutide, and tirzepatide, reinforcing comparable safety across agents in routine care.

Conexiant